Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAC: Tocilizumab for Painful Chronic Pancreatitis
2023-510084-35-00Phase 2Authorised
- Sponsor
- Aalborg University Hospital
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic pancreatitis (CP) comparing Tocilizumab (RoActemra) with Placebo (2 arms). Primary endpoint: COMPAT-SF total score at 24 weeks. Planned start Mar 2024; status: authorised.
02
Drugs
tocilizumab
03
Conditions
chronic pancreatitis (CP)
Beyond the preview
Go deeper on 2023-510084-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510084-35-00.